Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
196
resultados
Última actualización
22/10/2026 [07:56:00]
Resumen de: WO2025128082A1
A system and method for wireless transmission of glucose data. According to an embodiment of the present disclosure, there is provided a system, including: a glucose sensor; a beacon transmitter; and a processing circuit connected to the glucose sensor and the beacon transmitter, the processing circuit being configured to transmit a data packet, the data packet including measurement data including a measurement value, the measurement value being based on a glucose measurement.
Resumen de: US20260314958A1
0000 The present invention proposes a method of measuring the real-time level and degree of management of blood sugar based on an electrocardiogram. The method includes: obtaining an electrocardiogram signal measured for a user; estimating the user's blood sugar level by analyzing the electrocardiogram signal using a pre-trained first artificial intelligence, and determining whether the user has hyperglycemia or hypoglycemia by analyzing the electrocardiogram signal using an artificial intelligence; and determining whether the user needs guidance on blood sugar or diabetes based on the estimated blood sugar level and the result of the determination of whether the user has hyperglycemia or hypoglycemia. Through this, a user may check the user's immediate blood sugar level and how well the blood sugar is managed simply by measuring the electrocardiogram 10, and as a result, hyperglycemia and diabetes may be detected early or a complication attributable to hyperglycemia or diabetes may be prevented.
Resumen de: US20260315009A1
An autoregressive framework for synthetic data generation using an autoregressive generative model as an alternative to Generative Adversarial Networks (GAN). The autoregressive framework is applied to continuous glucose monitor data uses small real datasets to generate synthetic glycemic responses. The framework performs better than other systems because it works well with data constrained environments and can also evaluate contextual values in addition to past values.
Resumen de: WO2026214700A1
Provided in the present invention are a GLP-1/GLP-2 bispecific polypeptide and a fusion protein in which said polypeptide is fused to human IgG4-Fc. The GLP-1/GLP-2 bispecific polypeptide provided by the present invention can simultaneously activate GLP-1 and GLP-2 receptors, has a blood sugar control capability close to that of semaglutide, has a significant trophic effect on the small-intestine equivalent to that of teduglutide, and can markedly improve pathological features in mice with ulcerative colitis (UC).
Resumen de: AU2026242095A1
Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes 5 and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein. ep e p
Resumen de: WO2026217569A1
Methods and compositions for treating Alzheimer's disease and related neurodegenerative conditions using intranasal nose-to-brain delivery of ST266, an amnion-derived cell secretome are described. ST266 is a multi-component, acellular biologic composition produced from amnion-derived multipotent progenitor (AMP) cells under cGMP conditions and comprising a plurality of anti-inflammatory, neuroprotective, anti-apoptotic, and regenerative cytokines and growth factors. When administered intranasally, ST266 bypasses the blood-brain barrier and simultaneously targets multiple pathological mechanisms underlying Alzheimer's disease, including neuroinflammation, insulin dysregulation, oxidative stress, neuronal damage, and synaptic dysfunction. The invention encompasses pharmaceutical compositions formulated for intranasal nose-to-brain delivery, methods of treating Alzheimer's disease by administering such compositions, and methods of reducing neuroinflammation and improving insulin regulation in the central nervous system. The non-invasive nature of intranasal delivery offers significant advantages in patient compliance and minimization of systemic side effects.
Resumen de: US20260315694A1
0000 Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.
Resumen de: US20260314961A1
A blood glucose level measurement device includes a sensor portion that measures a blood glucose level of a user, a communication portion that transmits data representing the blood glucose level measured by the sensor portion to the outside, a flexible, sheet-shaped battery that supplies power to the sensor portion and the communication portion, a flexible, plate-shaped circuit portion that controls the operation of the communication portion, and an attachment portion configured to be attached to the body of the user. The battery has a peak current of 20 mA or more.
Resumen de: US20260321378A1
0000 Provided are systems and methods using which users may learn and become familiar with the effects of various aspects of their lifestyle on their health, e.g., users may learn about how food and/or exercise affects their glucose level and other physiological parameters, as well as overall health. In some cases the user selects a program to try; in other cases, a computing environment embodying the system suggests programs to try, including on the basis of pattern recognition, i.e., by the computing environment determining how a user could improve a detected pattern in some way. In this way, users such as type II diabetics or even users who are only prediabetic or non-diabetic may learn healthy habits to benefit their health.
Resumen de: US20260315755A1
Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
Resumen de: AU2026238070A1
11201607_1 (GHMatters) P110945.AU Disclosed is an expression regulatory system for cell-specific transcription (expression) of a protein of interest, for example a cell cycle inducer that reactivates proliferation in adult or neonatal cardiomyocytes or insulin-producing beta cells. The expression regulatory system comprises a first nucleic acid that encodes a microRNA recognition element that specifically binds a target cell miR, and a translation suppressor protein; and a second nucleic acid that comprises a suppressor protein interaction motif that binds the translation suppressor protein, and a gene that encodes a protein of interest. When a cell of interest is co-transfected with the first and second nucleic acids of the system, the protein of interest expressed in a cell-specific fashion. ep e p
Resumen de: EP4821428A2
0001 Digital and graphical user interfaces for multi-analyte monitoring systems are provided. For example, disclosed herein are various embodiments of methods, systems, and interfaces for alarm interfaces, alarm settings interfaces, alarm unavailability interfaces and features, and sensor results interfaces. Various embodiments of interfaces relating to glucose and ketone sensing are disclosed herein.
Resumen de: WO2025122639A1
Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.
Resumen de: US12758126B1
A wearable device is used to determine a glucose value for a portion of a user's body based on carbon dioxide emitted from the skin at the location of the wearable device. The device housing includes openings for carbon dioxide emitted by the user to enter and exit and may control accumulation of carbon dioxide within the housing using a valve, or allow carbon dioxide in the housing to reach an equilibrium value before determining a glucose value. Other sensors may be used to determine physiological or environmental factors, such as ambient carbon dioxide or increased respiration of the user, responsive to which a modifier may be applied to the determined glucose value.
Resumen de: US20260306030A1
0000 Embodiments relate to systems and methods for informing, determining, or controlling insulin dosage. The method involves generating plural disturbance profiles, each disturbance profile being a data representation based on historical patient data pertaining to a deviation from a threshold blood glucose level. The method involves receiving current patient data. The method involves applying a predictive model so that current patient data is compared to a disturbance profile and a probability analysis is used to assess the likelihood of a disturbance profile being an anticipated disturbance profile, the anticipated disturbance profile being a disturbance profile that is determined to match with the current patient data based on the probability analysis. The method involves determining an insulin dose amount based on the anticipated disturbance profile. The method involves outputting a signal representative of the insulin dose amount to a device configured for monitoring, influencing, and/or administering insulin levels in the patient.
Resumen de: US20260305986A1
Methods and apparatus for providing data processing and control for use in a medical communication system are provided. Such methods and apparatus may include determining a glucose value in a bodily fluid based on an estimated glucose temperature related signal and the glucose related signal in the bodily fluid, wherein the glucose temperature related signal may be estimated based on the temperature of the skin or the ambient temperature.
Resumen de: US20260311863A1
0000 According to an embodiment of the present disclosure, there is provided a method for assisting glycemic control of a subject using a computer system, the method including acquiring a self-set goal of the subject; acquiring GA values of the subject; generating a GA value trend using a plurality of the GA values; outputting the GA value trend to the subject; and outputting the self-set goal of the subject to the subject.
Resumen de: US20260305988A1
0000 A system for displaying blood glucose information includes a blood glucose monitoring device configured to monitor blood glucose levels of a user, and a display. The system may also include one or more processors, and a non-transitory computer-readable medium containing instructions that, when executed by the one or more processors, cause the system to perform operations. The operations may include obtaining the blood glucose levels from the blood glucose monitoring device, where the blood glucose levels include at least a current blood glucose level and a historic blood glucose level. The operations may also include presenting the current blood glucose level at a first location on the display based on a first scale, and presenting the historic blood glucose level at a second location on the display based on a second scale different from the first scale.
Resumen de: US20260306804A1
Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
Resumen de: US20260305987A1
0000 The present disclosure relates to a continuous blood glucose measurement device configured to prevent, in a state where a body attachment unit is inserted in and attached to a human body, an incision portion made by a guide needle from being formed to surround at least a part of a sensing area formed at a sensing member, whereby an incision portion is not formed around the sensing area so as to prevent the incision portion from causing a drop in a blood glucose measurement value and thus enable detection of an accurate blood glucose measurement value from the early stage of operation. Further, the guide needle has a shape not surrounding at least a part of the sensing area, so as to prevent, even without an additional device, the guide needle from forming an incision portion around the sensing area in a human body and thus enhance, by a simple structure, the accuracy of blood glucose measurement.
Resumen de: US20260309669A1
Creatinine levels may be monitored as a measure of kidney function. Conventionally, blood and/or urine tests are used for this purpose. Analyte sensors capable of monitoring creatinine in vivo may comprise: a sensor tail comprising at least a first working electrode, a creatinine-responsive active area disposed upon a surface of the first working electrode, a first membrane that is permeable to creatinine and overcoats the creatinine-responsive active area, and an oxygen scavenger located upon the sensor tail in proximity to the creatinine-responsive active area. The creatinine-responsive active area comprises a first electron transfer agent, a first polymer, and an enzyme system comprising multiple enzymes, particularly creatinine amidohydrolase, creatine amidinohydrolase, and sarcosine oxidase, that are capable of acting in concert to facilitate detection of creatinine. An oxidase enzyme may serve as the oxygen scavenger, particularly glucose oxidase when detecting creatinine in fluids also containing glucose.
Resumen de: WO2026212054A1
A method and smart glass for providing personalized information for health management are disclosed. The method comprises: acquiring an image through a camera; identifying at least one object included in the image acquired through the camera; acquiring sensing data related to blood glucose from an external electronic device; calculating at least one of a current blood glucose value and a predicted future blood glucose value based on the identified object and the sensing data; and displaying at least one of the current blood glucose value and the predicted future blood glucose value through a display.
Resumen de: US20260305975A1
0000 A non-invasive glycemic monitoring system uses a breath-sensing device to acquire repeated breath sessions from a user and to generate volatile organic compound information together with sample-quality and environmental information. A computing system receives a lab-derived A1C baseline for the user and uses the baseline with the breath-derived information to initialize and update a personalized model. Accepted breath sessions are stored in a rolling history and used to generate a projected A1C trend and a daily progress score or zone output representative of the user’s glycemic trajectory. In some embodiments, humidity, temperature, and sample-quality information are used to normalize breath-session data, and optional external inputs including finger-stick data, continuous glucose monitor data, or other external data are fused with the breath-derived information to refine personalization, anomaly handling, reporting, and confirmatory prompts.
Resumen de: WO2026211288A1
This liquid material for encapsulation at the time of intrauterine embryo transfer according to the present invention contains human serum albumin, glucose, alanyl-L-glutamine, hyaluronic acid, and two or more fatty acids. At least one unsaturated fatty acid selected from the group consisting of arachidonic acid, linoleic acid, linolenic acid, oleic acid, and palmitoleic acid and at least one saturated fatty acid selected from the group consisting of myristic acid, palmitic acid, and stearic acid are used as the two or more fatty acids.
Nº publicación: WO2026213025A1 08/10/2026
Solicitante:
DEXCOM INC [US]
DEXCOM, INC.
Resumen de: WO2026213025A1
The present examples relate generally to apparatuses, systems, and methods for force reduction for medical device sensors. The apparatuses, systems, and methods may be directed to force reduction for a transcutaneous analyte sensor for insertion into a host. The medical device may comprise an on-skin wearable medical device. The on-skin wearable medical device may include a transcutaneous glucose sensor.
BOPI
Sede Electrónica
